Development of new therapeutics for castration-resistant prostate cancer treatment

Castration-resistant prostate cancer is a late stage disease and many people die of it due to lack of effective therapeutic drugs. In the current project, we propose to develop new therapeutic drug a to specifically target CRPC’s common weak points, which are MCT4 and eIF4E gene’s proteint products that play very important roles in regulation of cancer cell’s energetic and protein translation pathways. The project aims to develop an antibody drug, an small molecule chemical drug and a nanoparticle drug to target MCT4 membrane protein and eIF4E transcription factor protein. If successful, the project will lead to new drug development for treating this deadly disease.

Faculty Supervisor:

Yuzhuo Wang

Student:

Partner:

Pharmaplanter Technologies Inc.

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

The University of British Columbia

Program: